SUBSCRIBE
SUBSCRIBE

AN2 Therapeutics, Inc.

NEWS
Biotech Bay
AN2 Therapeutics Nets $80 million for Novel Lung Disease Program
California-based AN2 Therapeutics secured $80 million in a Series B funding round to help advance its novel nontuberculous mycobacterial lung disease program.
January 7, 2022
 · 
2 min read
 · 
Alvin Clavines
IN THE PRESS
Press Releases
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
October 18, 2024
 · 
4 min read
Business
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
May 14, 2024
 · 
8 min read
Business
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
March 28, 2024
 · 
10 min read
Drug Development
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
February 12, 2024
 · 
6 min read
Biotech Bay
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
January 30, 2024
 · 
1 min read
Business
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 9, 2023
 · 
9 min read
Biotech Bay
AN2 Therapeutics to Present at Upcoming November 2023 Investor Conferences
November 6, 2023
 · 
1 min read
Biotech Bay
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
October 18, 2023
 · 
6 min read
Biotech Bay
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
October 11, 2023
 · 
5 min read
Biotech Bay
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
September 26, 2023
 · 
4 min read
Load More
JOBS